EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status

So Hyeon Kim, Yoonjung Park, Ahrum Min, Hye Yeon Park, Yu-Jin Kim, Sujin Ham, Jiwon Koh, Seongyeong Kim, Dae-Won Lee, Han Suk Ryu, Jin-Soo Kim, Kyung-Hun Lee und 1 weitere

Cancer Research and Treatment · 15.04.2026 · 58 (2) · 407-422

DOI: 10.4143/crt.2025.201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2026. Verfasst von So Hyeon Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, Seoul National University, Seoul, Korea. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, DNA Damage, Homologous Recombination. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Human epidermal growth factor receptor 2 (HER2) is amplified or overexpressed in various malignancies, including breast and gastric cancers, and is associated with poor prognosis. Although HER2-targeted therapies, such as trastuzumab, improve outcomes in HER2-positive tumors, resistance often develops, and HER2-low tumors remain largely untargeted. Trastuzumab deruxtecan (T-DXd; DS-8201a) is a HER2-targeted antibody-drug conjugate with potent activity in HER2-positive and HER2-low tumors. This study evaluates its antitumor mechanisms and efficacy in HER2-positive, HER2-low, and homologous recombination deficiency (HRD)–associated models.Materials and Methods Effects of T-DXd were assessed in cancer cell lines with diverse HER2 expression and HRD status. In vivo efficacy was evaluated using a xenograft model derived from HER2-low SNU-601 gastric cancer cells.

Results

T-DXd reduced HER2 phosphorylation and downstream signaling (AKT, ERK) in HER2-positive cells. It induced DNA damage accumulation, as evidenced by increased γH2AX and p-Chk1 expression, and triggered apoptosis through cleaved poly(ADP-ribose) polymerase and caspase-3 activation, confirmed by annexin V staining. Similar effects were observed in HER2-low cells, with greater sensitivity in HRD cells. In xenografts, T-DXd reduced tumor volume by up to 80% at 4 mg/kg and 10 mg/kg. Histological analyses showed decreased Ki-67 and increased apoptosis. Furthermore, T-DXd induced G2/M cell cycle arrest and nuclear anaplasia, suggesting disruption of chromosomal stability as a potential antitumor mechanism. No significant toxicity, including body weight loss, was observed.

Conclusion

These findings highlight T-DXd’s effectiveness in HER2-low and HRD tumors, supporting its broader clinical application, including strategies targeting DNA damage repair pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesTrastuzumabDNA DamageHomologous RecombinationImmunoconjugatesStomach NeoplasmsHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorFemaleApoptosisCamptothecin

Stichwörter der Autor:innen

DNA damageHER2Homologous recombination deficiencyNuclear anaplasiaTrastuzumab deruxtecan

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecanImmunoconjugatesCamptothecin

Autor:innen und Institutionen

  • Cancer Research Institute, Seoul National University, Seoul, Korea.
  • Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT

Zitieren

APA

Kim, S. H., Park, Y., Min, A., Park, H. Y., Kim, Y. J., Ham, S., Koh, J., Kim, S., Lee, D. W., Ryu, H. S., Kim, J. S., Lee, K. H., & Im, S. A. (2026). DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status. Cancer Research and Treatment, 58(2), 407-422. https://doi.org/10.4143/crt.2025.201

Vancouver

Kim SH, Park Y, Min A, Park HY, Kim YJ, Ham S, et al. DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status. Cancer Research and Treatment. 2026;58(2):407-422. doi:10.4143/crt.2025.201

BibTeX
@article{Kim2026,
  author = {Kim, So Hyeon and Park, Yoonjung and Min, Ahrum and Park, Hye Yeon and Kim, Yu-Jin and Ham, Sujin and Koh, Jiwon and Kim, Seongyeong and Lee, Dae-Won and Ryu, Han Suk and Kim, Jin-Soo and Lee, Kyung-Hun and Im, Seock-Ah},
  title = {DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status},
  journal = {Cancer Research and Treatment},
  year = {2026},
  volume = {58},
  number = {2},
  pages = {407--422},
  doi = {10.4143/crt.2025.201}
}
Kostenlos starten →